- Home
- GILD vs MRVL Comparison
GILD vs MRVL Comparison
Compare GILD & MRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MRVL
- Stock Information
- Founded
- GILD 1987
- MRVL 1995
- Country
- GILD United States
- MRVL United States
- Employees
- GILD N/A
- MRVL N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MRVL Semiconductors
- Sector
- GILD Health Care
- MRVL Technology
- Exchange
- GILD Nasdaq
- MRVL Nasdaq
- Market Cap
- GILD 119.7B
- MRVL 108.0B
- IPO Year
- GILD 1992
- MRVL 2000
- Fundamental
- Price
- GILD $109.95
- MRVL $103.79
- Analyst Decision
- GILD Buy
- MRVL Strong Buy
- Analyst Count
- GILD 27
- MRVL 28
- Target Price
- GILD $101.88
- MRVL $118.96
- AVG Volume (30 Days)
- GILD 7.6M
- MRVL 14.0M
- Earning Date
- GILD 02-11-2025
- MRVL 03-05-2025
- Dividend Yield
- GILD 2.87%
- MRVL 0.23%
- EPS Growth
- GILD N/A
- MRVL N/A
- EPS
- GILD 0.38
- MRVL N/A
- Revenue
- GILD $28,754,000,000.00
- MRVL $5,376,400,000.00
- Revenue This Year
- GILD $0.82
- MRVL $6.32
- Revenue Next Year
- GILD $3.21
- MRVL $42.26
- P/E Ratio
- GILD $289.34
- MRVL N/A
- Revenue Growth
- GILD 6.04
- MRVL N/A
- 52 Week Low
- GILD $62.07
- MRVL $53.19
- 52 Week High
- GILD $111.03
- MRVL $127.48
- Technical
- Relative Strength Index (RSI)
- GILD 75.82
- MRVL 42.72
- Support Level
- GILD $94.56
- MRVL $100.22
- Resistance Level
- GILD $106.69
- MRVL $112.50
- Average True Range (ATR)
- GILD 2.29
- MRVL 5.12
- MACD
- GILD 1.15
- MRVL -0.66
- Stochastic Oscillator
- GILD 93.47
- MRVL 16.54
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.